Faculty Profiles - ARIMA, Hiroshi

Papers - ARIMA, Hiroshi

Division display 21 - 40 of about 294 ／ All the affair displays >>

Impact of coronavirus disease 2019 on medical practice in endocrine and metabolic diseases in Japan: a nationwide surveillance study conducted by the Japan Endocrine Society Reviewed

Manaka, K; Kato, S; Sakamoto, R; Yamakage, H; Uema, T; Kawai, S; Shibata, M; Hiratsuka, I; Nakachi, S; Onoue, T; Tsuchiya, T; Fukui, M; Hashimoto, K; Suzuki, A; Makita, N; Ogawa, Y; Arima, H; Satoh-Asahara, N; Masuzaki, H

ENDOCRINE JOURNAL Vol. 71 ( 5 ) page： 499 - 514 2024

Effects of Digitization of Self-Monitoring of Blood Glucose Records Using a Mobile App and the Cloud System on Outpatient Management of Diabetes: Single-Armed Prospective Study. International journal

Tomoko Handa, Takeshi Onoue, Tomoko Kobayashi, Ryutaro Maeda, Keigo Mizutani, Ayana Yamagami, Tamaki Kinoshita, Yoshinori Yasuda, Shintaro Iwama, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Yoshinori Azuma, Takatoshi Kasai, Shuko Yoshioka, Yachiyo Kuwatsuka, Hiroshi Arima

JMIR diabetes Vol. 9 page： e48019 2024

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: In recent years, technologies promoting the digitization of self-monitoring of blood glucose (SMBG) records including app-cloud cooperation systems have emerged. Studies combining these technological interventions with support from remote health care professionals have reported improvements in glycemic control. OBJECTIVE: To assess the use of an app-cloud cooperation system linked with SMBG devices in clinical settings, we evaluated its effects on outpatient management of diabetes without remote health care professional support. METHODS: In this multicenter, open-label, and single-armed prospective study, 48 patients with diabetes (including type 1 and type 2) at 3 hospitals in Japan treated with insulin or glucagon-like peptide 1 receptor agonists and performing SMBG used the app-cloud cooperation system for 24 weeks. The SMBG data were automatically uploaded to the cloud via the app. The patients could check their data, and their attending physicians reviewed the data through the cloud prior to the patients' regular visits. The primary outcome was changes in glycated hemoglobin (HbA1c) levels. RESULTS: Although HbA1c levels did not significantly change in all patients, the frequency of daily SMBG following applying the system was significantly increased before induction at 12 (0.60 per day, 95% CI 0.19-1.00; P=.002) and 24 weeks (0.43 per day, 95% CI 0.02-0.84; P=.04). In the subset of 21 patients whose antidiabetic medication had not been adjusted during the intervention period, a decrease in HbA1c level was observed at 12 weeks (P=.02); however, this significant change disappeared at 24 weeks (P=.49). The Diabetes Treatment Satisfaction Questionnaire total score and "Q4: convenience" and "Q5: flexibility" scores significantly improved after using the system (all P<.05), and 72% (33/46) patients and 76% (35/46) physicians reported that the app-cloud cooperation system helped them adjust insulin doses. CONCLUSIONS: The digitization of SMBG records and sharing of the data by patients and attending physicians during face-to-face visits improved self-management in patients with diabetes. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) jRCTs042190057; https://jrct.niph.go.jp/en-latest-detail/jRCTs042190057.

DOI： 10.2196/48019

Web of Science

PubMed

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events Reviewed

Kobayashi, T; Iwama, S; Arima, H

ENDOCRINE JOURNAL Vol. 71 ( 1 ) page： 23 - 29 2024

A case of hypophysitis after COVID-19 vaccination with a detection of anti-pituitary antibody, with review of literature Reviewed

Kyo, C; Kobayashi, T; Iwama, S; Kosugi, R; Sawabe, F; Hayafusa, R; Sakai, Y; Ogawa, T; Kotani, M; Inoue, T; Arima, H; Ariyasu, H

ENDOCRINE JOURNAL Vol. 71 ( 8 ) page： 799 - 807 2024

Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade Reviewed

Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima

Endocrine Journal Vol. 71 ( 5 ) page： 515 - 526 2024

Improved glycemic control after the use of flash glucose monitoring accompanied by improved treatment satisfaction in patients with non-insulin-treated type 2 diabetes: A post-hoc analysis of a randomized controlled trial. Reviewed International journal

Ayaka Hayase, Takeshi Onoue, Tomoko Kobayashi, Eri Wada, Tomoko Handa, Tamaki Kinoshita, Ayana Yamagami, Yoshinori Yasuda, Shintaro Iwama, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Yachiyo Kuwatsuka, Masahiko Ando, Motomitsu Goto, Hiroshi Arima

Primary care diabetes Vol. 17 ( 6 ) page： 575 - 580 2023.12

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

AIMS: In our previously reported randomized controlled trial in patients with noninsulin-treated type 2 diabetes, the use of flash glucose monitoring (FGM) improved glycated hemoglobin (HbA1c), and the improvement was sustained after the cessation of glucose monitoring. In this post-hoc analysis, we examined data from our trial to identify the factors that influenced FGM efficacy. METHODS: We analyzed data for 48 of 49 participants of the FGM group who completed the trial to clarify the changes in various parameters and factors related to HbA1c improvement with the use of FGM. RESULTS: Analyses of the FGM data during the 12-week FGM provision period showed that the weekly mean blood glucose levels considerably decreased as early as at 1 week compared with the baseline values, and this decline continued for 12 weeks. An enhancement in the Diabetes Treatment Satisfaction Questionnaire regarding "willingness to continue the current treatment" score was significantly associated with the improvement in HbA1c at 12 (p = 0.009) and 24 weeks (p = 0.012). CONCLUSIONS: Glycemic control was improved soon after FGM initiation, accompanied by improved satisfaction with continuation of the current treatment in patients with noninsulin-treated type 2 diabetes.

DOI： 10.1016/j.pcd.2023.09.009

Web of Science

PubMed

肥満症診療の未来とAI活用生活習慣病診療において患者への介入・支援をどこまで機械・アプリケーションに任せられるのか

尾上剛史, 津下一代, 有馬寛

肥満研究 Vol. 29 ( 合同学術集会抄録集 ) page： 211 - 211 2023.11

Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline. Reviewed International journal

Xin Zhou, Shintaro Iwama, Tomoko Kobayashi, Masahiko Ando, Hiroshi Arima

The Journal of clinical endocrinology and metabolism Vol. 108 ( 10 ) page： E1056 - E1062 2023.9

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

CONTEXT: Positive antithyroglobulin (TgAb) and/or antithyroid peroxidase antibodies (TPOAb) at baseline indicate a high risk of thyroid immune-related adverse events (irAEs) induced by antiprogrammed cell death-1 antibodies (anti-PD-1-Ab). However, whether the positivity patterns of both antibodies are associated with the risk of thyroid irAEs is unknown. OBJECTIVE: The aim of the present study was to clarify the association of the pattern of TgAb and TPOAb positivity at baseline with the risk of thyroid irAEs induced by anti-PD-1-Ab. METHODS: Patients (n = 516) were evaluated for TgAb and TPOAb at baseline and prospectively for thyroid function every 6 weeks for 24 weeks after initiating anti-PD-1-Ab. RESULTS: Fifty-one (9.9%) patients developed thyroid irAEs (thyrotoxicosis in 34, hypothyroidism without prior thyrotoxicosis in 17). Twenty-five patients subsequently developed hypothyroidism following thyrotoxicosis. The cumulative incidence of thyroid irAEs differed among 4 groups classified by the presence of TgAb/TPOAb at baseline (group 1: TgAb-(-)/TPOAb-(-), 4.6% [19/415]; group 2: TgAb-(-)/TPOAb-(+), 15.8% [9/57]; group 3: TgAb-(+)/TPOAb-(-), 42.1% [8/19]; group 4: TgAb-(+)/TPOAb-(+), 60.0% [15/25]) as follows: groups 1 vs 2-4 (P ≤ .001) and groups 2 vs 3 (P = .008) and 4 (P < .001). There were different incidences of thyrotoxicosis (groups 1-4, 3.1%, 5.3%, 31.6%, 48.0%, respectively; P < .001) in groups 1 vs 3 and 4, and groups 2 vs 3 and 4, and of hypothyroidism (groups 1-4: 2.9%, 15.8%, 31.6%, 60.0%, respectively; P < .001) in groups 1 vs 2 to 4, and groups 2 vs 4. CONCLUSION: The risk of thyroid irAEs was affected by the pattern of TgAb and TPOAb positivity at baseline; there were high risks of thyrotoxicosis in patients with TgAb-(+) and of hypothyroidism in patients with TgAb-(+) and those with TPOAb-(+).

DOI： 10.1210/clinem/dgad231

Web of Science

PubMed

Generation and purification of ACTH-secreting hPSC-derived pituitary cells for effective transplantation. International journal

Shiori Taga, Hidetaka Suga, Tokushige Nakano, Atsushi Kuwahara, Naoko Inoshita, Yu Kodani, Hiroshi Nagasaki, Yoshitaka Sato, Yusuke Tsumura, Mayu Sakakibara, Mika Soen, Tsutomu Miwata, Hajime Ozaki, Mayuko Kano, Kenji Watari, Atsushi Ikeda, Mitsugu Yamanaka, Yasuhiko Takahashi, Sachiko Kitamoto, Yohei Kawaguchi, Takashi Miyata, Tomoko Kobayashi, Mariko Sugiyama, Takeshi Onoue, Yoshinori Yasuda, Daisuke Hagiwara, Shintaro Iwama, Yoshitaka Tomigahara, Toru Kimura, Hiroshi Arima

Stem cell reports Vol. 18 ( 8 ) page： 1657 - 1671 2023.8

Language：English Publishing type：Research paper (scientific journal)

Pituitary organoids are promising graft sources for transplantation in treatment of hypopituitarism. Building on development of self-organizing culture to generate pituitary-hypothalamic organoids (PHOs) using human pluripotent stem cells (hPSCs), we established techniques to generate PHOs using feeder-free hPSCs and to purify pituitary cells. The PHOs were uniformly and reliably generated through preconditioning of undifferentiated hPSCs and modulation of Wnt and TGF-β signaling after differentiation. Cell sorting using EpCAM, a pituitary cell-surface marker, successfully purified pituitary cells, reducing off-target cell numbers. EpCAM-expressing purified pituitary cells reaggregated to form three-dimensional pituitary spheres (3D-pituitaries). These exhibited high adrenocorticotropic hormone (ACTH) secretory capacity and responded to both positive and negative regulators. When transplanted into hypopituitary mice, the 3D-pituitaries engrafted, improved ACTH levels, and responded to in vivo stimuli. This method of generating purified pituitary tissue opens new avenues of research for pituitary regenerative medicine.

DOI： 10.1016/j.stemcr.2023.05.002

Web of Science

PubMed

ストレプトゾトシン糖尿病マウスにおける抗PD-1抗体の抗腫瘍効果低下とケモカインの関連

伊藤雅晃, 岩間信太郎, 安田康紀, 井土哲志, 奥地剛之, 山上綾菜, Xin Zhou, 小林朋子, 有馬寛

日本内分泌学会雑誌 Vol. 99 ( 3 ) page： 721 - 721 2023.7

線条体ニューロンにおけるPTP1Bは高脂肪食に対する報酬効果を増強する

久納光皓, 坂野僚一, 王思嫻, 佐々木智之, 孫汝楠, 廣瀬友矩, 杉山摩利子, 高木博史, 有馬寛

日本内分泌学会雑誌 Vol. 99 ( 1 ) page： 321 - 321 2023.5

高脂肪食摂取により生じる視床下部弓状核と中脳腹側被蓋野の炎症は自発運動により抑制される

佐々木智之, 杉山摩利子, 久納光皓, 孫汝楠, 廣瀬友矩, 高木博史, 坂野僚一, 有馬寛

日本内分泌学会雑誌 Vol. 99 ( 1 ) page： 322 - 322 2023.5

重症低ナトリウム血症の治療における血清ナトリウム濃度予測システムの精度検証

木下珠希, 萩原大輔, 東慶成, 大山慎太郎, 有馬寛

日本内分泌学会雑誌 Vol. 99 ( 1 ) page： 293 - 293 2023.5

PD-1遮断における甲状腺機能障害のリスクはベースライン時の抗甲状腺抗体陽性数によって層別化される(The risk of thyroid dysfunction in PD-1 blockade is stratified by the number of positive anti-thyroid antibodies at baseline.)

Zhou Xin, 岩間信太郎, 小林朋子, 山上綾菜, 井土哲志, 伊藤雅晃, 奥地剛之, 安田康紀, 有馬寛

日本内分泌学会雑誌 Vol. 99 ( 1 ) page： 314 - 314 2023.5

抗PD-1抗体関連甲状腺機能異常症の臨床的特徴と抗甲状腺抗体価との関連

山上綾菜, 岩間信太郎, 小林朋子, Zhou Xin, 伊藤雅晃, 奥地剛之, 安田康紀, 有馬寛

日本内分泌学会雑誌 Vol. 99 ( 1 ) page： 306 - 306 2023.5

ストレプトゾトシン糖尿病マウスにおける抗PD-1抗体の大腸癌細胞株に対する抗腫瘍効果低下とメモリーT細胞分画、PD-1発現およびPD-L1発現の検討

伊藤雅晃, 岩間信太郎, 安田康紀, 井土哲志, 奥地剛之, 山上綾菜, Zhou Xin, 小林朋子, 有馬寛

日本内分泌学会雑誌 Vol. 99 ( 1 ) page： 305 - 305 2023.5

【甲状腺疾患アップデート:明日から役立つ最新知見】薬剤性甲状腺機能異常症抗PD-1抗体による甲状腺障害の基礎と臨床

安田康紀, 岩間信太郎, 有馬寛

診断と治療 Vol. 111 ( 5 ) page： 665 - 668 2023.5

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：(株)診断と治療社

＜文献概要＞Headline 1 免疫チェックポイント阻害薬(ICI)による免疫関連有害事象(irAE)の発症が問題となっており,内分泌irAEでは抗PD-1抗体による甲状腺障害の発症頻度が高い.2 抗PD-1抗体による甲状腺障害の発症には抗PD-1抗体治療開始前の甲状腺自己抗体の存在が発症リスク因子であり,発症機序として細胞傷害性CD4陽性T細胞から放出されるグランザイムBによる直接的な甲状腺組織傷害の関与が示唆されている.3 ICI治療を安全に継続するためには,ICI治療開始前での甲状腺自己抗体を含む甲状腺機能のフォローと内分泌専門医との連携が重要である.

Other Link： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J00697&link_issn=&doc_id=20230518020024&doc_link_id=10.34433%2Fdt.0000000264&url=https%3A%2F%2Fdoi.org%2F10.34433%2Fdt.0000000264&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

Anti-tumor effects of anti-programmed cell death-1 antibody treatment are attenuated in streptozotocin-induced diabetic mice. Reviewed International journal

Masaaki Ito, Shintaro Iwama, Daisuke Sugiyama, Yoshinori Yasuda, Takayuki Okuji, Tomoko Kobayashi, Xin Zhou, Ayana Yamagami, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroyoshi Nishikawa, Hiroshi Arima

Scientific reports Vol. 13 ( 1 ) page： 5939 - 5939 2023.4

Authorship：Last author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

Hyperglycemia impairs immune response; however, it remains unknown whether the anti-tumor effects of anti-programmed cell death-1 antibody (PD-1-Ab) treatment are changed in hyperglycemic conditions. We analyzed the effect of PD-1-Ab on tumor growth in streptozotocin-induced diabetic mice (STZ-mice) subcutaneously inoculated with MC38 (a colon carcinoma cell line). Furthermore, we assessed the expression of chemokines by polymerase chain reaction (PCR) array in tumor-draining lymph nodes (dLNs) of these mice and MC38 cells cultured in different glucose concentrations. The suppressive effect of PD-1-Ab on tumor growth was attenuated. This was accompanied by fewer tumor-infiltrating CD8+ T cells, and STZ-mice had fewer tumor-infiltrating CD11c+ dendritic cells (DCs) than normoglycemic mice. mRNA expression levels of CXCL9, a chemokine recruiting CD8+ T cells, were lower in dLNs of STZ-mice than in normoglycemic mice after PD-1-Ab treatment, and its protein was expressed in DCs. In MC38 cells cultured with 25 mM glucose, mRNA expression of CCL7, a chemokine recruiting DCs, was decreased compared to cells cultured with 5 mM glucose. These results suggest that the STZ-induced hyperglycemia impairs the effect of PD-1-Ab treatment on MC38 tumor growth, and is accompanied by reduced infiltration of DCs and CD8+ T cells and decreased expression of CCL7 and CXCL9.

DOI： 10.1038/s41598-023-33049-7

Web of Science

PubMed

Generation of hypothalamic neural stem cell-like cells in vitro from human pluripotent stem cells. Reviewed International journal

Tsutomu Miwata, Hidetaka Suga, Yohei Kawaguchi, Mayu Sakakibara, Mayuko Kano, Shiori Taga, Mika Soen, Hajime Ozaki, Tomoyoshi Asano, Hiroo Sasaki, Takashi Miyata, Yoshinori Yasuda, Tomoko Kobayashi, Mariko Sugiyama, Takeshi Onoue, Hiroshi Takagi, Daisuke Hagiwara, Shintaro Iwama, Hiroshi Arima

Stem cell reports Vol. 18 ( 4 ) page： 869 - 883 2023.4

Authorship：Last author Language：English Publishing type：Research paper (scientific journal)

When damaged, restoring the function of the hypothalamus is currently impossible. It is unclear whether neural stem cells exist in the hypothalamus. Studies have reported that adult rodent tanycytes around the third ventricle function as hypothalamic neural stem cell-like cells. However, it is currently impossible to collect periventricular cells from humans. We attempted to generate hypothalamic neural stem cell-like cells from human embryonic stem cells (ESCs). We focused on retina and anterior neural fold homeobox (RAX) because its expression is gradually restricted to tanycytes during the late embryonic stage. We differentiated RAX::VENUS knockin human ESCs (hESCs) into hypothalamic organoids and sorted RAX+ cells from mature organoids. The isolated RAX+ cells formed neurospheres and exhibited self-renewal and multipotency. Neurogenesis was observed when neurospheres were transplanted into the mouse hypothalamus. We isolated RAX+ hypothalamic neural stem cell-like cells from wild-type human ES organoids. This is the first study to differentiate human hypothalamic neural stem cell-like cells from pluripotent stem cells.

DOI： 10.1016/j.stemcr.2023.02.006

Web of Science

PubMed

Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors Reviewed

Inaba, H; Morita, S; Kosugi, D; Asai, Y; Kaido, Y; Ito, S; Hirobata, T; Inoue, G; Yamamoto, Y; Jinnin, M; Kimura, H; Ota, M; Okudaira, Y; Nakatani, H; Kobayashi, T; Iwama, S; Arima, H; Matsuoka, T

FRONTIERS IN IMMUNOLOGY Vol. 14 page： 1165004 2023.4

　 PREV - NEXT 　

<ARIMA, Hiroshi>

Papers - ARIMA, Hiroshi